+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 40Years - 80Years
All Genders
ID07668518

Randomized, Double-Blind Study Evaluating Safety and Early Effects of Inhaled KIT2014 in Moderate to Severe COPD Patients with Dose Escalation

Led by Kither Biotech Srl · Updated on 2026-10-20

36

Participants Needed

3

Research Sites

17 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, pharmacokinetics, and early effectiveness of inhaled KIT2014 in patients with moderate to severe Chronic Obstructive Pulmonary Disease COPD. This multicenter, randomized, double-blind, placebo-controlled study includes a dose-ranging design with three ascending dose cohorts. It aims to better understand how KIT2014 behaves in the body and its potential effects over a short treatment period. Participants will receive inhaled KIT2014 or a placebo using a nebulizer. The treatment lasts for 7 days across three different dose levels in sequential cohorts. The study compares KIT2014 with placebo to assess safety and early responses to the drug within this timeframe. During the study, participants will be closely monitored for treatment-emergent adverse events and serious adverse events from the first dose through a follow-up visit on Day 9. Researchers will assess lung function and COPD symptoms according to established guidelines. The total participation period covers screening, 7 days of treatment, and monitoring through the follow-up visit to evaluate safety and tolerability.

CONDITIONS

Brief Title

A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of KIT2014 in Patients With Moderate to Severe COPD

Research Team

K

Katrina Asher

K

Kate Ramage

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here